Russia’s Sputnik Light vaccine shows 70% effectiveness against the Delta COVID-19 variant three months after injection.
The one-shot product is likely to become the country’s main vaccine, Russia’s sovereign wealth fund said on Wednesday.
The findings are part of a Russian push to promote Sputnik Light as an effective standalone vaccine and as a booster that can be combined with non-Russian vaccines.
The Russian Direct Investment Fund (RDIF) cited data submitted by Gamaleya Institute to medical website medRxiv ahead of a peer review. The data was based on 28,000 participants who received a dose of Sputnik Light and an unvaccinated control group of 5.6 million.
